Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults
BACKGROUND: Candidemia is a common cause of nosocomial bloodstream infection. When selecting therapeutic treatments for candidemia, cost-effectiveness is an important consideration. The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia.
Saved in:
Main Authors: | Coleman Rotstein, Lael Cragin, Michel Laverdière, Gary Garber, Eric J Bow, Alissa Scalera, Craig Roberts, Sonja V Sorenson, the Canadian Expert Panel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2008-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2008/161835 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada
by: Coleman Rotstein, et al.
Published: (2004-01-01) -
Antimicrobial Regimens Prescribed by Canadian Physicians for Chemotherapy-Induced Febrile Neutropenic Episodes
by: Michel Laverdière, et al.
Published: (1999-01-01) -
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective
by: Michel Laverdiere, et al.
Published: (2014-01-01) -
Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults
by: Eric J Bow, et al.
Published: (2010-01-01) -
An Assessment of Linezolid Utilization in Selected Canadian Provinces
by: Sandra Walker, et al.
Published: (2006-01-01)